Compare CNDT & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNDT | ACOG |
|---|---|---|
| Founded | 2016 | 2000 |
| Country | United States | United States |
| Employees | 51000 | N/A |
| Industry | Business Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.2M | 193.6M |
| IPO Year | 2016 | 2024 |
| Metric | CNDT | ACOG |
|---|---|---|
| Price | $1.65 | $8.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | ★ 885.4K | 89.3K |
| Earning Date | 11-06-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.58 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,042,000,000.00 | $10,220,275.00 |
| Revenue This Year | N/A | $152.34 |
| Revenue Next Year | N/A | $91.54 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.15 | $4.50 |
| 52 Week High | $2.82 | $10.14 |
| Indicator | CNDT | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 42.70 | 56.15 |
| Support Level | $1.52 | $5.49 |
| Resistance Level | $1.62 | $9.95 |
| Average True Range (ATR) | 0.08 | 0.47 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 7.50 | 93.62 |
Conduent Inc acts as a provider of business process services with expertise in transaction-intensive processing, analytics, and automation. The company provides industry-focused service offerings in growth markets such as Healthcare and Transportation, as well as provides multi-industry services such as transaction processing, customer care, and payment services. It operates through three segments, namely Commercial Industries, which is the key revenue-driving segment, Government Services, and Transportation. The group operates its business in the United States, Europe, and Other areas, of which the majority of revenue is generated in the United States.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.